The cost savings following the use of Iodixanol compared to Iopromide in coronarography averaged 2287 RUB (72 USD) in common population, 2866 RUB (USD91) in patients with CKD, and 3427 RUB (US$109) in patients with diabetes mellitus and CKD. CONCLUSIONS: The results of this study demonstrated Iodixanol to be costsaving compared to low-osmolar contrast media both in risk groups and in general population. OBJECTIVES: The Take Control of Your Blood Pressure trial randomized 636 community-dwelling individuals with hypertension to evaluate the impact of a telephonic behavioral self-management intervention, home blood pressure monitoring, and both interventions combined compared to usual care on reducing systolic blood pressure (SBP) over 24 months. At 24 months, the combined intervention demonstrated a signifi cant 3.9 mmHg (95%CI: 0.9,6.9) reduction in SBP relative to usual care. Patients randomized to home BP monitoring or the behavioral intervention had less improvement (0.6 mmHg and 0.6 mmHg, respectively). A prospective economic evaluation was performed. METHODS: Measures of medical resource use costs were derived from electronic data representing medical care delivered within the Duke University Health System. Intervention-related costs, including patient time, were estimated using patient-level data collected during the trial, administrative records, and published unit costs. Sensitivity analyses were conducted to evaluate the impact of changing assumptions about overhead costs and time between completed phone encounters when estimating costs associated with the behavioral intervention. RESULTS: On average, over 24 months, patients incurred $6,965 (SD 22,054) in inpatient costs and $8,676 (SD 9,368) in outpatient costs, with no signifi cant differences across intervention groups. When applying base-case assumptions, 24-month intervention costs were estimated to be $90 (SD 2) for home blood pressure monitoring, $345 (SD 64) for the behavioral intervention ($31 per phone encounter) and $416 (SD 93) for the combined intervention. In sensitivity analyses, the cost for each phone encounter ranged from approximately $10 to $45. Patient time costs were estimated at $585 (SD 487) for home monitoring, $55 (SD 16) for the behavioral intervention and $741 (SD 529) for the combined intervention. CONCLUSIONS: Home blood pressure monitoring and/or the behavioral intervention had little impact on medical resource use or costs over 2 years. Our analysis demonstrated that these interventions are cost-additive to the health care system and that patients' time costs are considerable.
PCV59 ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. THE DRIVER BARE METAL STENT: RESULTS FROM THE ENDEAVOR II TRIAL
Eisenstein EL 1 , Edwards R 1 , Cowper PA 1 , Kong DF 1 , Silverstein MD 2 , Mark DB 1 , Anstrom KJ 1 , Wijns W 3 1 Duke Clinical Research Institute, Durham, NC, USA, 2 Health Care Research, Bellaire, TX, USA, 3 Cardiovasculer Center, Aalst, Belgiun OBJECTIVES: To assessed the economic attractiveness of the Endeavor drug-eluting stent (DES) vs. the Driver bare metal stent (BMS) using 4-year follow-up information from the ENDEAVOR II clinical trial. METHODS: We used clinical, index procedure and follow-up events data from subjects randomized to receive Endeavor (n 598) vs. Driver (n 599), and applied Medicare cost and quality of life adjustments from secondary sources. We compared differences in clinical endpoints, medical costs, and quality adjusted survival through 4 years follow-up (1440 days). RESULTS: Patients in both treatment groups had similar baseline characteristics. The use of Endeavor vs. Driver reduced 4-year target vessel revascularization (TVR) rates per 100 subjects (10.4 vs. 21.5; difference, 11.1; 95% confi dence interval [CI], 16.0 to 6.1; p .001), with no difference in the rates per 100 subjects of death (5.0 vs. 5.2; difference, .2; 95% CI, 2.4 to 2.7; p .90) or non-fatal myocardial infarction (MI) (3.2 vs. 4.4; difference, 1.2; 95% CI, 3.4 to 1.0; p .29). After discounting at a 3% annual rate, there were no differences in quality-adjusted survival days (1093 vs. 1090; difference, 3; 95% CI, 13 to 19; p .69) and total medical costs ($21,483 vs. $21,680; difference, $198; 95% CI, $1608 95% CI, $ to $1207 . CONCLUSIONS: The use of Endeavor vs. Driver was associated with a signifi cant reduction in TVR through four years follow-up with no difference in death, non-fatal MI, quality-adjusted survival, or total medical costs. These results are comparable to those for other studies comparing DES vs. BMS. We analyzed case report form information from subjects randomized to receive Endeavor (n 323) vs. Cypher (n 113) stents, using quality of life adjustment and Medicare cost weights applied from secondary sources, and a $2100 cost for stents. We compared differences in outcomes and costs; and evaluated cost-effectiveness through 3-years follow-up (1080 days). RESULTS: The use of Endeavor vs. Cypher stents reduced the 3-year rates per 100 subjects of death or myocardial infarction (MI) (3.9 vs. 10.8; difference, 6.9; 95% confi dence interval [CI], 0.8 to 9.9; p .028), with no difference in target vessel revascularization rates (17.9 vs. 12.2; difference, 5.7; 95% CI, 3.9 to 15.1; p .23), but greater use of coronary artery bypass graft surgery (3.5 vs. 0.0; difference 3.5; 95% CI, 1.3 to 5.7; p .002). After discounting at 3% per annum, total medical costs for Endeavor vs. Cypher were similar ($23,353 vs. $21,657; difference, $1696; 95% CI, $1089 to $4482, p .23), and the 3-year cost-effectiveness ratio was $57,002 per quality-adjusted life year. CONCLUSIONS: Use of Endeavor vs. Cypher led to reductions in death or MI, with no differences in other outcomes. These fi ndings are unexpected in DES comparisons. If future trials observe similar differences, the use of Endeavor vs. Cypher will be economically attractive by conventional standards. A 1 year follow-up period was used and costs incurred after patients' initial hospital discharge were examined. In addition to ordinary least squares (OLS),, quantile-regression models (QRM) were used to identify drivers of posthospital costs. QRM make no assumption about the distribution of the error term and provide quantile-specifi c covariate effects, which is useful in applications with highly skewed data. RESULTS: OLS results indicated co-morbidity scores, prior health care costs and initial hospital diagnosis were main drivers of post-hospital discharge costs (p 0.01). Also, revascularization procedures during the initial hospitalization were not signifi cantly associated with post-hospital costs. QRM confi rmed the other fi ndings but showed, at the lower end of the post-hospital costs distribution, having revascularization procedures during the initial hospitalization was signifi cantly associated with higher post-hospital costs. This effect was not signifi cant in the upper quantiles. CONCLUSIONS: In this study, initial hospital diagnosis, higher co-morbidity scores and prior health care costs were associated with higher posthospital costs. Also, QRM showed revascularization procedures were drivers of cost for patients with lower post-hospital expenditures. This is an intuitive fi nding considering patients who have revascularization procedures may have more follow-up care compared to those without revascularization. However, these patients may have fewer secondary events requiring hospitalization, thus keeping them in the lower cost quantiles.
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